Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354246 · ClinicalTrials.gov registry record · Phase 1
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
A Phase 1 study of Multiple Myeloma and Lung Cancer, sponsored by Compugen.
- Active
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 9
- Study locations
NCT04354246 is a Phase 1 study of Multiple Myeloma and Lung Cancer that is active but no longer recruiting, run by Compugen. The registered enrollment target is 110 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT04354246, a Phase 1 study of Multiple Myeloma and Lung Cancer, is active but no longer recruiting, sponsored by Compugen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 9
- Study locations
Study Summary
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Conditions Studied
Interventions
- DRUG Dose escalation: COM902 monotherapy.
- COMBINATION_PRODUCT Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)
- DRUG Cohort expansion: COM902 (RDFE) monotherapy.
- DRUG Cohort expansion: COM902 in combination with COM701 (both at the RDFE).
- COMBINATION_PRODUCT Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Study Locations (9)
Texas
- Mary Crowley Cancer Research - Dallas
- MD Anderson Cancer Center. - Houston
- The START Center for Cancer Care. - San Antonio
Florida
- Florida Cancer Specialists - Sarasota
Massachusetts
- Massachusetts General Hospital. - Boston
Michigan
- START Midwest. - Grand Rapids
Ohio
- The Ohio State University Comprehensive Cancer Center. - Columbus
Tennessee
- The University of Tennessee WEST Cancer Center. - Memphis
Wisconsin
- Froedtert & Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2020-03-31 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04354246
The ClinicalTrials.gov registry entry for NCT04354246 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (80% lower). The listed sponsor is Compugen, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dose escalation: COM902 monotherapy. is the first listed.
NCT04354246 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Texas, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04354246 about?
NCT04354246 is a clinical study titled "COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies". Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
What is the current status of trial NCT04354246?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2020-03-31. Estimated completion is 2025-12-30.
What conditions does trial NCT04354246 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lung Cancer, Ovarian Cancer, Advanced Cancer, Colon Cancer.
What interventions are being tested in trial NCT04354246?
The interventions under investigation include: Dose escalation: COM902 monotherapy. (DRUG), Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE) (COMBINATION_PRODUCT), Cohort expansion: COM902 (RDFE) monotherapy. (DRUG), Cohort expansion: COM902 in combination with COM701 (both at the RDFE). (DRUG), Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab. (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04354246?
This trial is sponsored by Compugen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04354246 being conducted?
This trial has 9 study locations across Florida, Massachusetts, Michigan, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.